| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Icatibant |
| Brand | Firazyr® |
| Indication | For symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (type I and II HAE). |
| Assessment Process | |
| Rapid review commissioned | 22/07/2013 |
| Rapid review completed | 31/07/2013 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |